权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of genetic diagmosis for drug resistance in cancer

癌症耐药性基因诊断的发展

基本信息

批准号：
12672237
负责人：
FUNATO Tadao
金额：
$ 2.37万
依托单位：
Tohoku University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2000
资助国家：
日本
起止时间：
2000 至 2002
项目状态：
已结题

项目摘要

Drug resistance is acquired in the anticamcer drug in leukemia, and it is an important problem to become treatment resistance. Because of that, an anticancer drugresistant acquired is made clear, and the same has the gene which relates to the resistance, and it is necessary to decide early diagnosis. The various quantities to measure it in a small quantity were developed in the leukemia. First, the important factor involved in the acute leukemia cleared that it was deoxycytidine kinase (dCK) involved in a MDR1 gene to be involved in the multidrug resistance and a MRP1 gene, araCresistant. It was confirmed, and cut off value in the clinical inspection with patients, was established the quantitative way of detecting these amounts of genetic expression to establish realtime quantity to be excellent in the sensitivity and the peculiarity in the fundamental examination which it tried. The detection sensitivity of this way was high in comparison with usual multipledrug resistance, and it was shown by that result that it was useful for the diagnosis of anticancer resistant in the clinical target. Specially, relevance with the first treatment resistance and the amount of MDR1 expression with the acute leukemia and the recurrence was suggested, and it was shown that it was useful for the prediction of the treatment resistance in the MDR1 genetic. But, it isn't clear from the examination record until now, and it must pile up an examination more as for the relation between the amount of exprission and the treatment resistance between MRP1 and dCK. Therefore, it was proved that was the clinical way of introducing this way as an early diagnosis of anticancer resistant and of examining it, and clinical target meaning was explained. Furthermore, if it has the gene related to the resistance of every anticancer drug, it can be applied to the genetic quantity by this way, and it is suggested that it is useful for the comparison with the recent DNA array analysis

白血病患者对抗癌药物产生耐药性，成为治疗耐药的重要问题。因此，明确了获得的抗癌药物抗性，并且该抗性具有与抗性相关的基因，并且有必要决定早期诊断。在白血病中发展了各种量来测量它的少量。首先，对急性白血病的重要致病因素进行了研究，明确了多药耐药与MDR 1基因和MRP 1基因araC耐药相关的脱氧胞苷激酶（dCK）。它被证实，并与患者的临床检查中的截止值，建立了检测这些量的基因表达的定量方法，建立实时量在其尝试的基础检查中的灵敏度和特异性是优秀的。与常用的多重耐药检测方法相比，该方法的检测灵敏度高，可用于临床靶点的耐药诊断。特别是首次耐药率和MDR 1表达量与急性白血病及复发的相关性，表明MDR 1基因可用于急性白血病耐药的预测。但是，从目前的检测记录来看并不清楚，关于MRP1和dCK的表达量与处理抗性之间的关系还有待进一步的研究。因此，证明了引入该方法作为抗癌药耐药的早期诊断和检测的临床方法，并说明了临床靶向意义。此外，如果它具有与每种抗癌药物的耐药性相关的基因，则可以通过这种方式应用于遗传量，并且建议它有助于与最近的DNA阵列分析进行比较